Your A-Z of episodes

Did you know there’s even more we can do to promote your episode? Find out more…

  • Episode 199

    Charles River’s lifelong CDMO leader

    Kerstin Dolph

    / Charles River Laboratories

    Kerstin Dolph, SVP of Manufacturing at Charles River Labs, shares insights from her 23-year journey and diverse roles at the business.

  • Episode 198

    The pharma ingredients disruptor

    Jack Stine

    / Savendor

    Jack Stine, CEO at Savendor, shares his journey and motivations for launching his own business in the pharma outsourcing industry.

  • Episode 197

    Baking success to IQVIA exit

    Tessa Pugh

    / PharmaReview

    Tessa Pugh, ex-CEO at PharmaReview, shares her journey from co-founder to CEO, driving growth and leading a PE-backed exit to IQVIA.

  • Episode 196

    The biotech-MedTech CEO tackling obesity

    Camila Easter

    / Oxford Medical Products (OMP)

    Camila Easter, CEO at Oxford Medical Products, shares her journey from the veterinary field to making waves in the GLP-1 space.

  • Episode 195

    Delhi boy, done good

    Akshay Peer

    / Trakcel

    Akshay Peer, co-founder and SVP at TrakCel, joins the podcast to share why streamlining software is vital for the CGT space.

  • Episode 194

    Meet the Top Gun CDMO Maverick

    John Fowler

    / Pii (Pharmaceutics International, Inc.)

    John Fowler, CEO at Pii, joins the podcast to share insights on the skills needed to lead a successful CDMO in today’s challenging market.

  • Episode 193

    Pfizer’s retired manufacturing veteran

    Peter Stevenson

    / Independent Director and Pharma industry veteran

    Pharma industry veteran Peter Stevenson joins the podcast to share insights from his experience leading Pfizer’s CDMO, Pfizer CentreOne.

  • Episode 192

    Tasty Topics: Navigating Novo Nordisk’s Acquisition of Catalent

    Dirk Lange, Brett Alderson, John Cameron & Janet Hoogstraate

    / Pyramid Labs, NovaCina, Corden Pharma & NorthX Biologics

    Hear sector experts discuss the potential impacts of Novo’s acquisition of Catalent and maximizing GLP-1 manufacturing capacity.

  • Episode 191

    Reimagining drug development

    Jen Nwankwo

    / 1910 Genetics

    Jen Nwankwo, Founder and CEO of 1910 Genetics, recently joined the podcast to discuss how 1910 is reshaping the industry and drug discovery.

  • Episode 190

    A lifetime of drug hunting

    Karen Lackey

    / X-Chem

    Karen Lackey, CEO at X-Chem recently discussed why she moved away from Big Pharma after 30 years to move to a global CRO.

  • Load more